Stock Research for ICAD


Featured Broker: Ally Invest

Get the due diligence for another stock.


ICAD Stock Chart & Research Data

The ICAD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ICAD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ICAD Due diligence Resources & Stock Charts

The ICAD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ICAD Detailed Price Forecast - CNN Money CNN View ICAD Detailed Summary - Google Finance
Yahoo View ICAD Detailed Summary - Yahoo! Finance Zacks View ICAD Stock Research & Analysis -

Stock Analysis

TradeIdeas View ICAD Trends & Analysis - Trade-Ideas Barrons View ICAD Major Holders - Barrons
NASDAQ View ICAD Call Transcripts - NASDAQ Seeking View ICAD Breaking News & Analysis - Seeking Alpha
Spotlight View ICAD Annual Report - OTC Report View ICAD OTC Short Report -
TradeKing View ICAD Fundamentals - TradeKing Charts View ICAD SEC Filings - Bar Chart
WSJ View Historical Prices for ICAD - The WSJ Morningstar View Performance/Total Return for ICAD - Morningstar
MarketWatch View the Analyst Estimates for ICAD - MarketWatch CNBC View the Earnings History for ICAD - CNBC
StockMarketWatch View the ICAD Earnings - StockMarketWatch MacroAxis View ICAD Buy or Sell Recommendations - MacroAxis
Bullish View the ICAD Bullish Patterns - American Bulls Short Pains View ICAD Short Pain Metrics -

Social Media Mentions

StockTwits View ICAD Stock Mentions - StockTwits PennyStocks View ICAD Stock Mentions - PennyStockTweets
Twitter View ICAD Stock Mentions - Twitter Invest Hub View ICAD Investment Forum News - Investor Hub
Yahoo View ICAD Stock Mentions - Yahoo! Message Board Seeking Alpha View ICAD Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ICAD - Insider Cow View Insider Transactions for ICAD - Insider Cow
CNBC View ICAD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ICAD - OTC Markets
Yahoo View Insider Transactions for ICAD - Yahoo! Finance NASDAQ View Institutional Holdings for ICAD - NASDAQ

Stock Charts

FinViz View ICAD Stock Insight & Charts - StockCharts View ICAD Investment Charts -
BarChart View ICAD Stock Overview & Charts - BarChart Trading View View ICAD User Generated Charts - Trading View

Latest Financial News for ICAD

Long-Term Study of 1,000 Tumors Demonstrates Effectiveness of iCAD's Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment
Posted on Monday January 07, 2019

NASHUA, N.H., Jan. 07, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of a long-term study conducted at Hoag Memorial Hospital Presbyterian with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT). With a median follow-up of 36 months, outcomes published in the Annals of Surgical Oncology showed that breast cancer recurrence rates of patients who were treated with IORT using the Xoft System were comparable to those seen in the cornerstone, randomized TARGIT-A and ELIOT trials, which evaluated IORT using different technology.

Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
Posted on Thursday January 03, 2019

SAN DIEGO, Jan. 03, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.

iCAD Announces CFO Transition
Posted on Thursday December 27, 2018

NASHUA, N.H., Dec. 27, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology company providing innovative cancer detection and therapy solutions, today announced that Richard Christopher, Executive Vice President, Chief Financial Officer, is resigning from the Company to pursue another career opportunity, effective January 11, 2019. Mr. Christopher’s resignation is not the result of any dispute or disagreement with iCAD or any matter relating to the Company’s accounting practices or financial statements.

iCAD, Inc. Announces $7.0 Million Private Placement of Unsecured Subordinated Convertible Debentures
Posted on Thursday December 20, 2018

NASHUA, N.H., Dec. 20, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a  global medical technology company providing innovative cancer detection and therapy solutions, today announced that it has entered into definitive agreements to sell unsecured subordinated convertible debentures, due three years following issuance, to certain institutional and accredited investors, including participation by all directors and executive officers of iCAD, in a private placement with gross proceeds of approximately $7.0 million.  iCAD expects to close the sale of the debentures on or about December 21, 2018, subject to the satisfaction of customary closing conditions. With the recent U.S. FDA clearance of ProFound AI for mammography, a high-performance, cancer detection AI technology, the company will have added funds to bolster its commercial capability in what is a substantial addressable market.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.